ADIPOQ and type 2 diabetes mellitus: Pioglitazone increases high molecular weight adiponectin and decreases TNF-α levels and RBP-4 levels in patients with type 2 diabetes[155-157].In addition, this effect of pioglitazone on plasma levels of adiponectin is highly predictable on baseline levels[158].